FAM131B

Across TCGA pan-cancer cohorts, FAM131B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FAM131B data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher FAM131B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM131B expression acts as an unfavorable survival marker.

SCLC, SARC, and LIHC are the cancer types where FAM131B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	18	view →
SARC	DFS	Median	All	0.157	0.614	.001	12	view →
LIHC	DFS	Median	All	0.094	0.555	.002	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FAM131B–SCLC (DFS)

Open the SCLC breakdown →